Drug Profile


Alternative Names: ISIS-301012; Kynamro; Mipomersen sodium

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Genzyme Corporation; Isis Pharmaceuticals; Kastle Therapeutics
  • Class Antihyperlipidaemics; Antisense oligonucleotides; Oligodeoxyribonucleotides
  • Mechanism of Action Apolipoprotein B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type IIa
  • Phase III Hypercholesterolaemia
  • No development reported Atherosclerosis

Most Recent Events

  • 26 Jul 2017 Phase-III development for Heterozygous Familial Hypercholesterolaemia (Adjunctive treatment) is ongoing in countries worldwide (SC) (Kastle Therapeutics website, July 2017)
  • 03 May 2016 Kastle Therapeutics acquires Mipomersen from Ionis Pharmaceuticals
  • 01 Feb 2016 Genzyme completes a phase III trial in severe heterozygous familial Hypercholesterolaemia (Adjunctive treatment) in USA, Canada, Israel, South Africa, Argentina, Australia, Belgium, Brazil, Croatia, Czech Republic, Denmark, Germany, Greece, Hong Kong, Hungary, India, Italy, South Korea, Malaysia, Netherlands, New Zealand, Norway, Poland, Russia, Spain, Sweden, Taiwan, Turkey, Ukraine and United Kingdom (SC) (NCT01475825)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top